News

Friday, 12. April 2019 | Filed under Company News

Company News: Curetis’ Subsidiary Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019

        

— Strain-typing and AMR detection of clinical isolates based on ARESdb

— Set-up of own NGS service laboratory in Vienna, Austria

Ares Genetics GmbH (Ares Genetics), a Curetis Group Company (Curetis N.V.; EURONEXT: CURE), today announced the introduction of new service offerings in molecular microbiology at the upcoming 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place in Amsterdam, the Netherlands, on April 13-16, 2019.  Read more…

Thursday, 11. April 2019 | Filed under Company News

Company News: Curetis Publishes Full-Year 2018 Financial Results and Updated Guidance for 2019

– Launched Unyvero System and Unyvero LRT Cartridge in the U.S.

– Increased revenues to EUR 1.4 million in 2018

– Raised EUR 19.5 million additional funding

– Revised focus and strategy

Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the financial results for the twelve months ended December 31, 2018, and provided an updated guidance for 2019. Read more…

Friday, 5. April 2019 | Filed under Company News

Company News: Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019

— Company to host earnings conference call on same day

Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it will publish its full-year 2018 financial results on April 11, 2019. In addition, the Company will host a public earnings conference call and webcast on April 11, 2019, at 03:00 pm CET / 09:00 am EDT to present the financial results of 2018, highlight the most important events in 2018 and provide an outlook for 2019. Read more…